Sort   by:  
 Page size 
TranscriptomicsLong-term Exposure to Sorafenib of Liver Cancer Cells Induces Resistance with Epithelial-to-Mesenchymal Transition, Increased Invasion and Risk of Rebound Growth
Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but its use is hampered by the occurrence of drug resistance. To investigate the molecular mechanisms involved we developed five resistant human liver cell lines in which we studied morphology, gene expression a...
ORGANISM(S): Homo sapiens 
2016-03-14 | E-GEOD-62813 | biostudies-arrayexpress
UnknownEverolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
Not available
S-EPMC5791842 | biostudies-literature
ModelsClaret2009 - Predicting phase III overall survival in colorectal cancer
Claret2009 - Predicting phase III overall survival in colorectal cancer This model is described in the article: Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. Claret L, Girard P, Hoff PM, Van Cutsem E, Zuide...
2017-08-31 | MODEL1708310001 | BioModels
TranscriptomicsCombining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.
Objective: Insights about differences in tumor vasculature and how it reacts to VEGF inhibition is limited, but nevertheless of major relevance to anti-angiogenic therapy. In this study we therefore characterize the effect of bevacizumab combined with chemoradiotherapy (CRT), and explore molecular a...
ORGANISM(S): Homo sapiens 
2016-08-02 | E-GEOD-60331 | biostudies-arrayexpress
UnknownEverolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
Not available
S-EPMC5950503 | biostudies-literature
UnknownBody Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.
Not available
S-EPMC5070548 | biostudies-literature
UnknownPhase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Not available
S-EPMC6075847 | biostudies-literature
Sort   by:  
 Page size